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Autoantibodies against myeloid lysosomal enzymes in crescentic gb-
merulonephritis. To investigate the possible association of crescentic
glomerulonephritis (CON) with autoantibodies to myeloid lysosomal
enzymes, we tested sera from 35 consecutive patients with CON
without diagnostic immunohistological findings in their renal biopsy for
the presence of antineutrophil cytoplasmic antibodies directed against a
29 kD antigen from azurophilic granules (29 kD-ANCA), against my-
eloperoxidase (MPO-ANCA) and against elastase (elastase-ANCA),
using antigen-catching ELISAs with well-defined monoclonal antibod-
ies. 29 kD-ANCA were present in the sera of all nine patients with CON
as part of biopsy-proven Wegener's granulomatosis (WG), of ten
patients with CON and clinically suspected WO, and of two patients
with idiopathic CON. Sera from the remaining patients with clinically
suspected WG (N = 5)or idiopathic CGN (N = 6) were negative for 29
kD-ANCA, but invariably positive for MPO-ANCA. Neither of these
antibodies could be detected in sera from patients with CON of
infectious origin (N = 3), different forms of CON (N = 7), other renal
lesions (N = 34), or normal controls (N = 52). None of the sera tested
were positive for elastase-ANCA. Our results indicate that both vascu-
litis-associated CON and idiopathic CGN are associated with autoanti-
bodies against myeloid lysosomal enzymes. This finding places these
disorders within one spectrum of diseases.
Crescentic glomerulonephritis (CGN) is a rare histopatho-
logic finding observed only in ito 2% of renal biopsy specimens
in most series [1]. Its clinical counterpart is designated as
rapidly progressive glomerulonephritis [2]. CON is associated
with multisystem disorders as Wegener's granulomatosis, sys-
temic lupus erythematosus and Henoch-Schönlein purpura, or
with infectious disorders as bacterial endocarditis [2]. In addi-
tion, it may occur in patients without a definite diagnosis of a
systemic illness [1, 3—5]; some of these patients, however, have
symptoms compatible with systemic vasculitis [2, 6—8]. Classi-
fying the latter patients as vasculitis is hampered by the lack of
tissue confirmation from a representative vasculitic lesion [6,
9]. On the other hand, systemic vasculitides may start as a
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single organ disease, for instance as kidney limited polyarteritis
or Wegener's granulomatosis [8, 10, 11].
In most cases of untreated CGN renal function deteriorates to
the point of renal failure [1, 2]. In the past several years a
dramatic improvement in the prognosis of CGN as part of
systemic vasculitis has been reported with different immuno-
suppressive regimens [6]. Since the time interval between initial
symptoms and start of immunosuppressive therapy directly
affects prognosis, early diagnosis is of crucial importance [12].
For reasons mentioned before, diagnosis frequently is delayed
in patients without an obvious diagnosis of a systemic illness.
Recently, autoantibodies against cytoplasmic constituents of
neutrophils and monocytes (ACPA or c-ANCA) have been
detected in sera from patients with systemic vasculitis [13—21],
especially Wegener's granulomatosis and microscopic poly-
arteritis. These antibodies are directed against a 29 kD protein
from the azurophilic granules [22] with serine protease activity
(29 kD-ANCA) [23, 241, probably proteinase-3 [24, LUdemann,
personal communication]. In addition, we have demonstrated
autoantibodies to myeloperoxidase (MPO) and elastase [25],
different lysosomal enzymes, in sera from vasculitis patients.
MPO-ANCA were described by Falk and Jennette [19] in
patients with vasculitis associated and idiopathic necrotizing
and crescentic glomerulonephritis. The specificity of this find-
ing in relation to the presence of 29 kD-ANCA has not been well
delineated, partly due to the high background levels that were
observed in their assays. The availability of monoclonal anti-
bodies against these three enzymes enabled us to develop
sensitive and specific ELISA tests for the detection of antibod-
ies to these antigens.
To investigate the possible association of crescentic glomer-
ulonephritis with autoantibodies to myeloid lysosomal enzymes
in more detail, we tested the sera of 35 consecutive patients
with CON without diagnostic immunohistological findings for
the presence of these antibodies. In addition, sera from patients
with different forms of CGN or other forms of glomerulonephn-
tis were tested as well. Our results indicate that, within the
spectrum of glomerulonephritis, both vasculitis-associated and
idiopathic CGN are specifically associated with autoantibodies
to myeloid lysosomal enzymes. These findings suggest that
idiopathic CGN is related to the spectrum of vasculitides.
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Methods
Patients and renal biopsy specimens
The files of the Renal Pathology Service at the University
Hospital of Groningen were reviewed and biopsies diagnosed
between June 1984 and March 1988 as crescentic glomerulone-
phritis (CGN) were identified. Biopsies were re-evaluated by
one of us (JDE) who was not informed about the results of the
serological studies. Crescents were defined as aggregates of
cells proliferating in Bowman's space associated with fibrin
demonstrable by light or immunofluorescence (IF) microscopy
[4]. Glomeruli were considered to contain crescents only if 25%
or more of Bowman's space was occupied by extracapillary
cellular proliferation [4].
Out of 530 renal biopsy specimens seen at the Department of
Pathology during the study period, 42 biopsies showed focal
segmental or diffuse CGN by light microscopy. On further
histological evaluation including IF microscopy, biopsies from
seven patients showed CGN with typical immunohistological
findings and were excluded from the study population: one
biopsy from a patient with anti-GBM nephritis, two biopsies
from patients with systemic lupus erythematosus (SLE), two
biopsies from patients with Henoch-SchOnlein purpura, and
two biopsies from patients with membrano-proliferative gb-
merubonephntis. IF staining in the remaining 35 biopsy speci-
mens was regarded as having no diagnostic significance, al-
though IF findings were not always truly negative [1], since 10
specimens showed granular deposits of 1gM and complement
lacking a specific pattern.
The clinical and laboratory data of these 35 patients were
reviewed without knowledge of the serological findings. Clinical
findings were reviewed with special attention to respiratory
involvement, ocular manifestations, cutaneous vasculitis, pe-
ripheral nerve lesions, cardiac involvement and joint involve-
ment.
A diagnosis of Wegener's granulomatosis (WG) [26] was
made when CGN was accompanied by upper or lower respira-
tory lesions and when tissue biopsies showed extravascular
granulomatous inflammation ("biopsy proven WG"). When
granulomas were not found in biopsy specimens but nonspecific
granulation tissue was present, the condition was designated as
"clinically suspect for WG" [26]. Serum samples of all 35
patients, obtained within one week of renal biopsy, were tested
for autoantibodies to lysosomal enzymes. As controls we tested
serum samples from patients with other types of glomerulone-
phritis. These serum samples, which were also obtained within
one week of renal biopsy, were from the seven patients with
CGN with diagnostic immunohistological findings (see above),
11 patients with (non-crescentic proliferative) SLE nephritis, 12
patients with IgA nephropathy, and 11 patients with membra-
noproliferative glomerulonephritis. In addition, we tested se-
rum samples from patients with tuberculosis (N = 12), sarcoi-
dosis (N = 16) and normal controls (N = 52).
Methods
Detection of autoantibodies by indirect immunofluorescence.
Anticytoplasmic antibodies (ANCA) were detected by indirect
IF as described previously [15]. Staining patterns were de-
scribed as "cytoplasmic" (c-ANCA) when granular staining of
the cytoplasm with accentuation between the nuclear lobes was
present (Fig. 1) [15, 27], and as "perinuclear" when a (peri)
nuclear pattern was observed (Fig. 2) [27]. Antinuclear antibod-
ies (ANA) were detected by indirect IF on human fibroblast
monolayers.
Monoclonal antibodies to myeloid lysosomal enzymes. The
IgGi monoclonal antibody against the 29 kD-ANCA-antigen
(MoAb 12.8) [24, 28] was prepared by intraperitoneal immuni-
zation of a (Balb/c x AIJ)F1 mouse (CAF/l) with saline-
extracted azurophilic granule proteins (alpha-extract, isolated
by nitrogen cavitation of neutrophils according to the method of
Borregaard et al [29] followed by Percoll density-gradient
centrifugation). In a sandwich ELISA, one of the monoclonal
antibodies thus obtained appeared to bind specifically to the
antigen caught from the alpha-extract preparation by plastic-
coated IgG antibodies purified from c-ANCA-positive patient's
serum, but not to antigen caught by rabbit anti-elastase (pro-
vided by Dr. J.A. Kramps, University Hospital, Leiden, The
Netherlands). This (IgGi) monoclonal antibody was directed
against the c-ANCA antigen as was demonstrated by sequential
immunoprecipitation with c-ANCA-positive patient's sera and
it did not bind to purified elastase (Elastin products, Pacific,
Missouri, USA), purified myeloperoxidase (Elastin products) or
cathepsin G (Protagen AG, Laufelfringen, Switzerland) as was
demonstrated by immunoprecipitation (Fig. 3) and in a solid
phase ELISA [24]. This monoclonal antibody produced a
c-ANCA pattern on human granulocytes by indirect IF.
The IgG 1 monoclonal antibodies against myeloperoxidase
[30] (MoAb 7.17, Central Laboratory of the Bloodtransfusion
Service (CLB), Amsterdam, the Netherlands) and against
elastase [31] (MoAb NP57, from Dr. D.Y. Mason, Oxford, UK)
produced a perinuclear staining pattern on human granulocytes
by indirect IF. As non-related monocbonal antibody, a mouse
IgG 1 monoclonal antibody directed against a CMV-induced
cellular membrane antigen (C40), produced in our laboratory,
was used [32].
Detection of autoantibodies by ELISA. Microtiter plates
(Inotech) were incubated with 100 pi of 1:50 dilution of goat-
antimouse Ig (CLB, Amsterdam) in 0.1 Mcarbonate buffer (pH
9.6) for 48 hours at 4°C. After washing thoroughly with 10 mM
TRJS/HCL pH 8.0 containing 0.15 M NaCI and 0.05% Tween-20
(washing buffer), the plates were incubated with 100 .d of a
1:1000 dilution of the various monocbonal antibodies in 100 mM
TRIS/HCL pH 8.0 containing 0.25% Tween-20, 0.30 M NaC1,
1% BSA and 1% normal goat serum (incubation buffer) for two
hours at 37°C. After washing, the plates were incubated over-
night at 4°C with 1:1000 dilution of an extract of azurophilic
granules (lysosomes) of normal human neutrophils (2 mg/mI) in
incubation buffer. The extract of the azurophilic granules was
isolated according to the method of Borregaard et al in the
presence of protease inhibitors [29]. Subsequently, different
dilutions of test serum (starting with 1:100) diluted in the
incubation buffer were added for one hour at 37°C. After
washing bound antibody was detected by affinity purified F(ab)2
goat anti-human IgG linked to alkaline phosphatase and p-
nitrophenyl-phosphate disodium as a substrate. The optical
density at 405 nm was measured. The dilution curve of the
reference serum is shown in Figure 4. Concentrations were
computed from the linearized titration curve obtained after
log-logit transformation of the concentrations in the reference
serum and the corresponding absorbances. Antibody concen-
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Fig. 1. Staining of cytoplasmic components of fixed granulocytes by indirect immunofluorescence by a serum from a patient with active
Wegener's granulomatosis. A typical example of c-ANCA is seen.
Fig. 2. (Peri)nuc!ear staining pattern of fixed granulocyzes by indirect immunofluorescence by a serum from a patient with idiopathic crescentic
glomerulonephritis.
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Fig. 3. Immunoprecipitation of different myeloid lysosomal enzymes
by mouse monoclonal antibodies and patients' sera. a) MoAb 12.8:
monoclonal antibody against the 29 kD-ANCA antigen; b) 29 kD-
ANCA positive serum; c) MoAb NP57: monoclonal antibody against
elastase; d) elastase-ANCA positive serum; e) MoAb 4.15: monoclonal
antibody against myeloperoxidase; t) MPO-ANCA positive serum.
Table 1. Clinical findings and organ system involvement in 35
patients with crescentic glomerulonephritis (CON)
Biopsy Clinically CGN of
proven suspected Idiopathic infectious
WG WG CON origin(N = 9) (N = 15) (N = 8) (N = 3)
Mean age yrs 61 56 64 48
Male: female ratio 4:5 7:8 5:3 1:2
Organ involvement n fl n n
Kidney 9 15 8 3
—dialysis required 4 6 2 2
Lung 6 9 — —
—alveolar hemorrhage 2 6 — —
Paranasal sinuses 6 9 — —
Nose or nasopharynx 8 12 — —
Ear 7 7 — —
Joints 7 9 3 —
Eye 5 8 — —
Skin 4 6 — 1
Nervous system 8 3 — —
Heart 3 2 — I
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Fig. 4. ELISA for 29 kD-ANCA. Dilution curves of standard serum
(EJ—D), 29 kD-ANCA positive serum (O—O) and normal control
serum (L—t). Standard deviations of triplicates are shown.
tration in the reference serum (= the international standard
serum from the Statens Seruminstitut, Copenhagen, Denmark
[27]) was arbitrarily fixed at 100 U/mi.
Resuits were corrected for background staining by testing
each serum additionally by an ELISA identical to that de-
scribed, with the exception that a non-related monoclonal
antibody directed against a cytomegalovirus-specific glycopro-
tein [32] was used. Patient scm positive for 29 kD-ANCA,
MPO-ANCA and elastase-ANCA as demonstrated by immuno-
precipitation (Fig. 3) served as positive controls. To rule out
The 35 renal biopsies showing crescentic glomerulonephritis
(CON) without diagnostic immunohistological findings were
from 17 male and 18 female patients. The mean age at the time
of the renal biopsy was 58 years (range: 14 to 77 years). Renal
function was impaired in all patients. Fourteen patients re-
quired dialysis. The median plasma creatinine of the remaining
21 patients was 373 .tmoUliter (range 94 to 809 molIliter).
Microscopic hematuria and proteinuria were present in all
patients.
One out of these 35 patients had bacterial endocarditis and
two patients had a preceding streptococcal infection. In the
remaining 32 patients no infectious cause could be identified.
Nine of these 32 patients had biopsy-proven Wegener's granu-
lomatosis (WG); in 15 patients WG was clinically suspected,
and the remaining eight patients were classified as idiopathic
CGN although a systemic illness was suggested in three of them
by the presence of arthritis and fever. Organ system involve-
ment in the 35 patients with CON is summarized in Table 1.
Detection of autoantibodies by ELISA using different
monoclonal antibodies as catching antibodies
Antibodies reactive to the 29 kD-ANCA-antigen were ob-
served in 21 sera from patients with CON (Fig. 5). These
patients had biopsy proven WG (N = 9), clinically suspected
WG (N 10) or idiopathic CGN (N = 2). Eleven sera from
patients with CON were negative for 29 kD-ANCA and positive
for MPO-ANCA by ELISA (Fig. 6). These 11 patients had
clinically suspected WG (N = 5) or idiopathic CGN (N = 6).
Clinical findings in patients with clinically suspected WG are
shown in Table 2. All patients with MPO-ANCA and clinically
suspected WG presented with alveolar hemorrhage, while pa-
Mr(>< io-}
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45
31
21
14 Abbreviation is: WO, Wegener' s granulomatosis.
rheumatoid factor as a confounding variable in the catching
ELISA's 15 sera with high titers of rheumatoid factor were
tested. In none of these sera positive results for 29 kD-ANCA,
MPO-ANCA or elastase-ANCA were found.
Results
I
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Fig. 5. Anti-neutrophi! cytoplasmic antibodies directed to the 29 kD-
antigen (29 kD-ANCA) detected by ELISA in sera from several groups
of patients. ELISA was performed with a monoclonal antibody against
the 29 kD-ANCA-antigen as described in Methods. Sera were tested
from patients with crescentic glomerulonephritis without diagnostic
immunohistological findings in the biopsy (CON), other forms of
crescentic glomerulonephritis (0CGN), systemic lupus erythematosus
with non-crescentic glomerulonephritis (SLE), membranoproliferative
glomerujonephntis (MPGN), IgA nephropathy (IgA) and normal con-
trols (controls). Solid squares represent sera that demonstrate c-ANCA
by indirect immunofluorescence (lIP) on fixed granulocytes, solid
circles represent sera producing the (pen) nuclear staining pattern by
hF, and open circles represent sera with negative hF findings.
tients with clinically suspected WG and 29 kD-ANCA more
frequently had upper respiratory tract involvement. None of the
sera from the three patients with CGN of infectious origin were
positive by antigen-specific ELISA. None of the sera from
patients with different renal lesions, tuberculosis or normal
donors were positive by the 29 kD-ANCA and/or MPO-ANCA
specific ELISA's. All sera from patients with sarcoidosis were
negative for 29 kD-ANCA, one out of these 16 sera, however,
was weakly positive (5 U/mI) for MPO-ANCA. Antibodies to
elastase assayed by ELISA were not found in any of the sera.
Detection of anticytoplasmic antibodies by indirect
immunofluorescence
c-ANCA (Fig. 1) was found in 21 sera from the 35 patients
with CGN. All these sera were positive for 29 kD-ANCA by
ELISA. Sera from 12 out of the 35 patients with CGN produced
a (peri)nuclear staining pattern of granulocytes (Fig. 2). Two
out of these 12 sera were positive for MPO-ANCA as well as for
antinuclear antibodies, nine were positive for MPO-ANCA
only. The remaining serum with (pen)nuclear staining was
positive for antinuclear antibody only and was derived from a
patient with CGN of infectious origin. The sera of the other two
patients with CGN of infectious origin showed negative IF
findings on granulocytes.
Neither the sera from patients with other forms of CGN,
SLE-nephritis, membranoproliferative glomerulonephritis and
IgA nephropathy, nor other control sera were positive for
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Fig. 6. Anti-myeloperoxidase (MPO) antibodies detected by ELISA in
sera from several groups of patients. ELISA was performed with a
monoclonal antibody against MPO as described in Methods. See Fig. 5
for explanation and abbreviations.
Table 2. Clinical findings and organ system involvement in 15
patients with crescentic glomerulonephritis and clinically suspected
Wegener's granulomatosis (WG)
Clinically suspected Clinically suspected
WG with 29 kD- WG with MPO-
ANCA ANCA
Organ involvement (N = 10) (N = 5)
Kidney 10 5
—dialysis required 6 —
Lung 4 5
—alveolar hemorrhage 1 5
Paranasal sinuses 7 2
Nose or nasopharynx 9 3
Ear 6 1
Joints 6 3
Eye 7 1
Skin 6 —
Nervous system 3 —
Heart 2 -
c-ANCA. (Peri)nuclear staining was produced by four sera from
patients with other forms of CGN and by nine out of 11 sera
from patients with non-crescentic SLE nephritis. All these sera
had antinuclear antibodies, but none were positive for MPO-
ANCA. None of the sera from patients with different renal
lesions or from normal donors demonstrated a (peri)nuclear
staining pattern. These data are summarized in Table 3.
In addition, all sera from patients with sarcoidosis showed
negative IF findings. Two out of 12 sera from patients with
tuberculosis, however, produced a (peri)nuclear staining pat-
tern, Both sera were negative for antinuclear antibodies and
MPO-ANCA as measured by ELISA.
Discussion
In the present study all our consecutive patients with vascu-
litis associated and idiopathic CGN had autoantibodies directed
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Table 3. Indirect immunofluorescence (hF) findings on fixed
granulocytes and antibodies to 29 kD-ANCA-antigen and
myeloperoxidase (MPO) by ELISA in patients with different renal
disorders and normal controls
(Peri)nuclear
c- 29 kD- staining
Diagnosis ANCA ANCA by pattern MPO-ANCA
(number of by hF ELISA by hF by ELISA
patients tested) N N N N
Biopsy proven WO 9 9 0 0(N = 9)
Clinically suspected 10 10 5 5
WG (N = 15)
Idiopathic CGN 2 2 6 6(N=8)
CON of infectious 0 0 1 0
origin (N = 3)
Different forms of 0 0 4 0
CON (N =7)
Non crescentic SLE 0 0 9 0
nephritis (N = 11)
IgA nephropathy 0 0 0 0(N = 12)
Membranoproliferative 0 0 0 0
glomerulonephritis
(N= 11)
Normal donors 0 0 0 0
(N = 52)
Abbreviations are: WG, Wegener's granulomatosis; CON, crescentic
glomerulonephritis.
to cytoplasmic antigens of granulocytes and monocytes, either
to the 29 kD-ANCA antigen or MPO. c-ANCA or ACPA as
defined by hF staining pattern on fixed granulocytes have been
detected in the sera of patients with Wegener's granulomatosis
(WG) [15, 17, 20, 211. In addition, a solid phase radioimmuno-
assay has been reported to detect antibodies to cytoplasmic
constituents of neutrophils in sera from patients with WG and
microscopic polyarteritis [16]. In the latter assay sera from
patients with SLE, rheumatoid arthritis (RA) or scleroderma
gave positive results as well [16], probably due to the impurity
of the neutrophil extract used as a substrate in the assay.
Recently, Falk and Jennette [19] described a solid phase
ELISA for detection of ANCA using an unfractioned nitrogen
cavitate of neutrophils as the antigenic substrate. Their results
show a rather low specificity of their ANCA-ELISA for WG
and related disorders; 5% of normal blood donors and 73% of
patients with SLE nephritis had positive results as well. The
low specificity of the ELISA for WG may be explained from the
relatively crude material used as antigenic substrate. In the
present study, we applied an antigen-specific ELISA using a
well characterized monoclonal antibody to catch the 29 kD
antigen recognized by ANCA. In contrast to the former assays,
our 29 kD-ANCA ELISA did not produce positive results in
sera from patients with SLE nephritis, renal disorders different
from CGN or normal donors. All sera showing the typical
c-ANCA by hF, however, were also positive by ELISA.
Apart from c-ANCA highly specific for WG [15, 17, 20, 21],
a perinuclear staining pattern of neutrophils was observed by
hF in some sera from patients with vasculitis-like disorders
during routine testing for ANCA [27]. This bright staining
pattern was difficult to distinguish from the more homogeneous
nuclear fluorescence pattern produced, for example by antihis-
tone antibodies in patients with SLE and RA. The latter
antibodies, however, produce nuclear fluorescence also on
substrates different from granulocytes whereas many sera with
(peri)nuclear fluorescence on granulocytes tested in our labora-
tory were negative in routine ANA tests. Granulocyte-specific
ANA (GS-ANA) have been described in patients with RA [33].
The antigen(s) recognized by GS-ANA have not been well
characterized, but antibodies against elastase, MPO and some
other cytoplasmic constituents of neutrophils produce similar
staining patterns by hF on ethanol fixed granulocytes [34].
Therefore, we developed ELISA assays for detecting MPO-
ANCA and elastase-ANCA using monoclonal antibodies to
MPO and elastase, respectively [25].
Independently, Falk and Jennette [19] found antibodies with
reactivity to myeloperoxidase in patients with systemic vascu-
litis and idiopathic necrotizing and crescentic glomerulonephri-
tis. In addition, they described [35] the specific clinical patho-
logical correlations of their patients with pauci-immune
necrotizing glomerulonephritis. c-ANCA was correlated with
granulomatous inflammation, inflammatory lung or sinus dis-
ease, while the perinuclear pattern (p-ANCA) was found in
pulmonary capillaritis or renal limited disease. Recently, we
have found MPO-ANCA also in patients with limited WG [36],
and in patients with classic polyarteritis nodosa or the Churg
Strauss syndrome without renal manifestations of vasculitis
(manuscript in preparation).
Our findings in patients with CON are in accordance with the
observations of Falk and Jennette. Indeed, we found 29 kD-
ANCA in all patients with biopsy proven WG, in the majority of
patients with clinically suspected WG and in a minority of
patients with idiopathic CON. In addition, MPO-ANCA were
found in the remaining patients with clinically suspected WG
and idiopathic CGN who were negative for 29 kD-ANCA by
ELISA. All patients with MPO-ANCA and clinically suspected
WG presented with alveolar hemorrhage, while patients with
clinically suspected WG and 29 kd-ANCA more frequently had
upper respiratory tract involvement (Table 2).
Follow-up studies showed decreasing titers during treatment
and rising titers during relapses of the disease. Conversion of
autoantibodies (from 29 kD-ANCA to MPO-ANCA or vice
versa) was never observed. Thus, based on these findings we
found a sensitivity of 29 kD-ANCA for biopsy proven or
clinically suspected WG of 79% and a specificity of 29 kD-
ANCA, in a selected group of patients with glomerulonephritis,
of 96%. The sensitivity and specificity of MPO-ANCA for
idiopathic CON were 75% and 92%, respectively. Taken to-
gether, all our patients with vasculitis-associated or idiopathic
CON had either 29 kD-ANCA or MPO-ANCA. This demon-
strates that idiopathic CGN may be included in the spectrum of
systemic vasculitides such as Wegener's granulomatosis and
microscopic PAN. This might have important therapeutic con-
sequences.
The high degree of sensitivity and specificity of 29 kD-ANCA
and/or MPO-ANCA for CON suggests a pathogenetic role for
these antibodies. Recently, Bonsib [37] showed that damage to
the mesangial matrix may be the primary lesion in CON and
probably precedes GBM disruption, while the formation of
crescents may simply be a consequence of 'healing." This
lesion may result from lytic factors produced by either mesan-
gial or inflammatory cells. Lytic factors implicated are prote-
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ases, reactive oxygen species, halide ion and lymphokines.
Indeed, myeloperoxidase and the proteolytic myeloid lysoso-
ma! enzymes localize, in perfusion experiments, in the glomer-
uli, and can disrupt the capillary loop basement membrane
integrity [38—40]. The possibility that activated neutrophils may
have an important pathogenic role is further suggested by the
observation that intra-vascular lysis [41] and rapid turnover [42]
of neutrophils occur in patients with WG. It has been reported
that ANCA and also their F(ab)2 fragments can penetrate living
neutrophils [15], which might activate the neutrophil to release
the above-mentioned lytic factors. Otherwise, ANCA may be
implicated in (local) formation of immune complexes. MPO-
ANCA may also amplify the neutrophil-induced damage by
inactivating MPO, which is a potent terminator of the influx of
granulocytes by inactivating humoral factors such as chemotax-
ins [43] and an effective inhibitor of hydroxy! radical production
[44].
In conclusion, we have demonstrated the presence of either
29 kD-ANCA or MPO-ANCA by antigen-specific ELISA in the
sera from all patients with vasculitis-associated and idiopathic
CGN. This observation places idiopathic CGN, microscopic
PAN and WG within one spectrum of diseases with a probably,
comparable pathogenesis in which these autoantibodies may
play a central role.
Acknowledgments
This study was supported by grants C 84.514 and C 85.552 from the
Dutch Kidney Foundation.
We acknowledge the help and cooperation of the patients, the
referring physicians, our specialist colleagues and our house staff.
Particular thanks are due to Dr. F.J. van der Woude (University
Hospital, Leiden, The Netherlands) and Dr. P.C. Limburg for valuable
discussion, Dr. C,T. Buiter for providing ear, nose and throat consul-
tation on these patients, Dr. C.E. van der Schoot (CLB, Amsterdam)
for providing the monoclonal antibody against myeloperoxidase, Dr.
D.Y. Mason (Oxford, United Kingdom) for providing the monoclonal
antibody against elastase, Dr. J.A. Kramps (University Hospital,
Leiden, The Netherlands) for providing the rabbit anti-elastase used in
this study, Dr. P.E. de Jong, Dr. W. van Luijk and Dr. W. Reitsma-
Bierens for cooperation in obtaining clinical data, Dr. J Steensma and
Dr. D.S. Postma for samples from tuberculosis and sarcoidosis pa-
tients, Miss Coby van der Veen for technical assistance and Miss Kiki
Bugter for typing the manuscript.
Reprint requests to J. W. Cohen Tervaert, Department of Internal
Medicine, University Hospital, Oostersingel 59, 9713 EZ Groningen,
The Netherlands.
References
I. COUSER WG: Idiopathic rapidly progressive glomerulonephritis.
Am J Nephrol 2:57—69, 1982
2. GLAssocK RJ, COHEN AH, ADLER S, WARD H: Rapidly progres-
sive glomerulonephritis, in The Kidney (3rd ed), edited by BREN-
NER BM, RECTOR FC,, Philadelphia, WB Saunders Company,
1986, pp. 939—946
3. BEIRNE GJ, WAGNILD JP, ZIMMERMAN SW, MACKEN PD,
BURKHOLDER PM: Idiopathic crescentic glomerulonephritis. Med-
icine 56:349—381, 1977
4. STILMANT MM, BOLTON WK, STURGILL BC, SCHMIrF GW,
COUSER WG: Crescentic glomerulonephritis without immune de-
posits: Clinicopathologic features. Kidney mt 15:184—195, 1979
5. NEILD GH, CAMERON iS, OGG CS, TURNER DR, WILLIAMS DG,
BROWN CB, CHANTLER C, HICKS J: Rapidly progressive glomeru-
lonephritis with extensive glomerular crescent formation. Q J Med
207:395—416, 1983
6. VELOSA JA: Idiopathic crescentic glomerulonephritis or systemic
vasculitis. (Editorial) Mayo Clin Proc 62:145—147, 1987
7. HEPTINSTALL RH: Crescentic glomerulonephritis, in Pathology of
the Kidney (3rd ed), edited by HEPTINSTALL RH, Boston, Little,
Brown and Company, 1983, pp. 443—477
8. CROCKER BP, LEE T, GUNNELLS JC: Clinical and pathological
features of polyarteritis nodosa and its renal limited variant: Pri-
mary crescentic and necrotizing glomerulonephritis. Hum Pathol
18:38—44, 1987
9. SEu& A, CAMERONJS,TURNER DR, HARTLEY B, OGG CS, NEILD
GH, WILLIAMS DG, TAUBE D, BROWN CB, HICKS JA: Vasculitis
affecting the kidney: Presentation, histopathology and long-term
outcome. QJMed2IO:181—207, 1984
10. VAN DER WOUDE FJ, HOORNTJE SJ, WEENING JJ, VAN OVERBEEK
JiM, VAN DER HEM GK: Renal involvement in Wegener's granu-
lomatosis. Report of three unusual cases. Nephron 32:185—187,
1982
11. WOODWORTH TS, ABUELO JG, AUSTIN HA, ESPARZA A: Severe
glomenilonephritis with late emergence of classic Wegener's gran-
ulomatosis. Report of 4 cases and review of the literature. Medicine
66:181—191, 1987
12. WEISS MA, CRISSMAN JD: Segmental crescentic glomerulonephri-
tis: Diagnostic, prognostic and therapeutic significance. Am J
Kidney Dis 6:199—211, 1985
13. DAVIES DJ, MORAN JE, NIALL JF, RYAN GB: Segmental necrotiz-
ing glomerulonephritis with antineutrophil antibody: Possible arbo-
virus aetiology? Br Med J 285:606, 1982
14. HALL JB, WADHAM BMCN, WooD CJ, ASHTON V. ADAM WR:
Vasculitis and glomerulonephritis: A subgroup with an antineutro-
phil cytoplasmic antibody. Aust NZ J Med 14:277—278, 1984
15. VAN DER WOUDE FJ, RASMUSSEN N, LOBATTO S, WIIK A, PERMIN
H, VAN Es LA, VAN DER GIESSEN M, VAN DER HEM GK, THE TH:
Autoantibodies to neutrophils and monocytes: A new tool for
diagnosis and marker of disease activity in Wegener's granuloma-
tosis. Lancet i:425—429, 1985
16. SAVAGE COS, JONES 5, WINEARLS CG, MARSHALL PD, LocK-
wOOD CM: Prospective study of radioimmunoassay for antibodies
against neutrophil cytoplasm in diagnosis of systemic vasculitis.
Lancet i:l389—l393, 1987
17. LUDEMAN G, GRoss WL: Autoantibodies against cytoplasmic
structures of neutrophil granulocytes in Wegener's granulomatosis.
Clin Exp Immunol 69:350—375, 1987
18. PARLEVLIET LU, HENZEN-LOGMANS SC, OE PL, BRONSVELD W,
BALM AiM, DONKER AiM: Antibodies to components of neutro-
phil cytoplasm: A new diagnostic tool in patients with Wegener's
granulomatosis and systemic vasculitis. Q J Med 249:55—63, 1988
19. FALK RJ, JENNETTE JC: Anti-neutrophil cytoplasmic auto-anti-
bodies with specificity for myeloperoxidase in patients with sys-
temic vasculitis and idiopathic necrotizing and crescentic glomeru-
lonephritis. N EngI J Med 318:1651—1657, 1988
20. SPECKS V, WHEATLEY CL, MCDONALD TJMc, ROHRBACH MS,
DEREMEE RA: Anticytoplasmic autoantibodies in the diagnosis and
follow-up of Wegener's Granulomatosis. Mayo Clin Proc 64:28—36,
1989
21. COHEN TERVAERT JW, VAN DER WOUDE FJ, FAUCI AS, AMBRUS
JL, VELOSA J, KEANE WF, MEUER 5, VAN DER GIESSEN M, THE
TH, VAN DER HEM GK, KALLENBERG CGM: Association between
active Wegener's Granulomatosis and anticytoplasmic antibodies.
Arch mt Med (in press)
22. GOLDSCHMEDING R, TETTEROO PAT, THE TH, VON DEM BORNE
AEGKR: Wegener's Granulomatosis specific autoantibodies. Char-
acterization of the antigen. Kidney mt (abstract) 32:799, 1987
23. GOLDSCHMEDING R, TEN BOKKEL HUININK D, FABER N, TET-
TEROO PAT, HACK CE, VON DEM BORNE AEGKR: Identification of
the ACPA antigen as a novel myeloid lysosomal serine protease.
APMIS (suppl 6) 97:46, 1989
24. GOLDSCHMEDING R, VAN DER SCHOOT CE, TEN BOKKEL HUININK
D, HACK CE, VAN DER ENDE ME, KALLENBERO CGM, VON DEM
BORNE AEGKR: Wegener's Granulomatosis autoantibodies iden-
tify a novel DFP-binding protein in the lysosomes of normal human
neutrophils. J Clin Invest (in press)
25. GOLDSCHMEDING R, COHEN TERVAERT JW, VAN DER ScHoo'r CE,
VAN DER VEEN C, KALLENBERG CGM. VON DEM BORNE AEGKR:
806 Cohen Tervaert et a!: Autoantibodies in crescentic glomerulonephritis
ANCA, anti-myeloperoxidase and anti-elastase: three members of
a novel class of autoantibodies against myeloid lysosomal enzymes.
(suppi 6) APMIS 97:48—49, 1989
26. MCCLUSKEY RT, FIENBERG R: Vasculitis in primary vasculitides,
granulomatoses and connective tissue diseases. Hum Pathol 14:
305—315, 1983
27. RASMUSSEN N, WIIK A, HOIEN-MADSEN M, BORREGAARD N,
WOUDE FJ VAN DER: Anti-neutrophil cytoplasm antibodies 1988.
Lancet i:706-707, 1988
28. GOLDSCHMEDING R, VAN DER SCHOOT CE, VAN DER SNOEK MA,
VON. DEM BORNE AEGKR: A monoclonal antibody against the 29
kD ANCA-antigen: Application as catching antibody in a sandwich
ELISA for ANCA-detection. (suppl 6) APMIS 97:47, 1989
29. BORIEGAARD N, HEIPLE JM, SIMONS ER, CLARK RA: Subcellular
localization of the b-cytochrome component of the human neutro-
phil microbicidal oxidase: Translocation during activation. J Cell
Bio197:52—61, 1983
30. SCHOOT CE VAN DER, VON DEM BORNE AEGKR, TETTEROO PAT:
Characterization of myeloid leukemia by monoclonal antibodies,
with an emphasis on antibodies against myeloperoxidase. Ada
Haematologia (suppl 1) 78:32—40, 1987
31. PULFORD KAF, ERBER WN, CRICK JA, OLssoN I, MICKLEM KJ,
GATTER KC, MASON DY: Use of monoclonal antibody against
human neutrophil elastase in normal and leukaemia myeloid cells. J
Cliii Pathol 41:853—860, 1988
32. VOORT LHM VAN DER, LEU LFMH DE, THE TH: Characterization
of membrane antigens on human cytomegalovirus infected fibro-
blasts recognized by human antibodies. J Virol 63:1485—1488, 1989
33. Wiu A: Granulocyte specific antinuclear antibodies. Allergy 35:
263—289, 1980
34. PRYZWANSKY KB, MARTIN LE, SPITZNAGEL JK: Immunocyto-
chemical localization of myeloperoxidase, lactoferrin, lysozyme
and neutral proteases in human monocytes and neutrophilic gran-
ulocytes. J Reticuloendothel Soc 24:295—310, 1978
35. JENNETTE JC, FALK RJ: Anti-neutrophil cytoplasmic autoantibod-
ies. (letter) N EngI J Med 319: 1417, 1988
36. GANS ROB, GOLDSCHMEDING R, D0NKER AiM, HOORNTJE SJ,
KUIZENGA MC, COHEN TERVAERT JW, KALLENBERG CGM, VON
DEM BORNE AEGKR: Neutrophil cytoplasmic autoantibodies and
Wegener's Granulomatosis. (letter) Lancet i:269—270, 1989
37. BONSIB SM: Glomerular basement membrane necrosis and cres-
cent organization. Kidney mt 33:966-974, 1988
38. DAVIES M, BARNETT AJ, TRAVIS J, SANDERS E, COLES GA: The
degradation of human glomerular basement membrane with purified
lysosomal proteinases: Evidence for the pathogenetic role of poly-
morphonuclear leucocyte in glomerulonephritis. Cliii Sd Mo! Med
54:233—240, 1978
39. SHAH SV, BARICOS WH, BAse! A: Degradation of human glomer-
ular basement membrane by stimulated neutrophils. Activation of a
metalloproteinase(s) by reactive oxygen metabolites. J C/in Invest
79:25—31, 1987
40. JOHNSON RJ, COUSER WG, Cm EY, ADLER S, KLEBANOFF SJ:
New mechanisms for glomerular injury. Myeloperoxidase-hydro-
gen peroxide-halide system. J Cliii Invest 79:1379-1387, 1987
41. DONALD KJ, EDWARDS RL, McEV0Y JDS: An ultrastructural
study of the pathogenesis of tissue injury in limited Wegener's
granulomatosis. Pathology 8:161—169, 1976
42. DALE DC, FAUCI AS, WOLFF SM: The effect of cyclophosphamide
on leucocyte kinetics and susceptibility to infection in patients with
Wegener's granulomatosis. Arthr Rheum 16:657-664, 1973
43. CLARK RA, SZOT S: Chemotactic factor inactivation by stimulated
human neutrophils mediated by myeloperoxidase-catalyzed methi-
onine oxidation. J lunmunol 128:1507—1513, 1982
44. WINTERBOURN CC: Myeloperoxidase as an effective inhibitor of
hydroxyl radical production. Implications for the oxidative reac-
tions of neutrophils. J Clin Invest 78:545—550, 1986
